Список проголосовавших за комментарий " Proteon Therapeutics downgraded to Neutral at H.C. Wainwright; tgt lowered to $3 (1.75)H.C. Wainwright downgrades PRTO to Neutral from Buy and lowers their tgt to $3 from $18. Firm notes, on March 16, mgmt announced several protocol amendments to the ongoing Patency-2 study investigating the use of Proteon's lead product candidate, vonapanitase, during radiocephalic arteriovenous fistula (RC AVF) surgery in order to prolong vascular patency. <strong>While firm believes the new amendments help clear up the regulatory path for vonapanitase going forward, they also believe that there is still uncertainty regarding the potential pricing and commercial viability of the drug.</strong> Furthermore, in their view, there is a shortage of potential catalyst events in the next 6-8 months, which could render the share price range-bound. At this time, they are stepping to the sidelines until they gain better clarity on vonapanitase pricing and visibility on meaningful catalysts."